Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bloch

Showing results (151-160 of 672) with videos related to

Pageof 68
Sort By:
Therapeutique (La Semaine Des Hopitaux)|December 1, 1970
[Clinical study of citiolone, cyto-membranous hepatic protector]A Varay, A Castel, J Bloch
Emergency Medicine Journal : EMJ|October 19, 2013
Simulation training based on observation with minimal participation improves paediatric emergency medicine knowledge, skills and confidenceScott A Bloch, Amy J Bloch
Journal of the American Society of Hypertension : JASH|December 15, 2015
Ambulatory blood pressure monitoring to diagnose hypertension--an idea whose time has comeMichael J Bloch, Jan N Basile
Revue Medicale Suisse|December 12, 2007
[Fetal programming: an underestimated risk factor for cardiovascular and metabolic diseases]J Bloch, U Scherrer, C Sartori
The New England Journal of Medicine|April 26, 1979
Prednisone and beclomethasone for treatment of asthmaR J Dattwyler, K J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)|July 16, 2010
Is there accord in ACCORD? Lower blood pressure targets in type 2 diabetes does not lead to fewer cardiovascular events except for reductions in strokeMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|July 16, 2010
Intensive blood pressure control in children slows progression of chronic kidney diseaseMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|October 2, 2010
Meta-analysis concludes angiotensin receptor blocker use increases the risk of developing cancer: concerns about the science and the messageMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|November 9, 2010
In navigator, the angiotensin receptor blocker valsartin modestly reduced the progression to type 2 diabetes but had no effect on cardiovascular events in higher-risk patients with impaired glucose toleranceMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|January 11, 2011
Treating the black hypertensive in 2010: achieve lower targets while awaiting more definitive evidenceMichael J Bloch, Jan N Basile
Pageof 68

Showing results (151-160 of 672) with videos related to

Sort By:
Pageof 68
Therapeutique (La Semaine Des Hopitaux)|December 1, 1970
[Clinical study of citiolone, cyto-membranous hepatic protector]A Varay, A Castel, J Bloch
Emergency Medicine Journal : EMJ|October 19, 2013
Simulation training based on observation with minimal participation improves paediatric emergency medicine knowledge, skills and confidenceScott A Bloch, Amy J Bloch
Journal of the American Society of Hypertension : JASH|December 15, 2015
Ambulatory blood pressure monitoring to diagnose hypertension--an idea whose time has comeMichael J Bloch, Jan N Basile
Revue Medicale Suisse|December 12, 2007
[Fetal programming: an underestimated risk factor for cardiovascular and metabolic diseases]J Bloch, U Scherrer, C Sartori
The New England Journal of Medicine|April 26, 1979
Prednisone and beclomethasone for treatment of asthmaR J Dattwyler, K J Bloch
Journal of Clinical Hypertension (Greenwich, Conn.)|July 16, 2010
Is there accord in ACCORD? Lower blood pressure targets in type 2 diabetes does not lead to fewer cardiovascular events except for reductions in strokeMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|July 16, 2010
Intensive blood pressure control in children slows progression of chronic kidney diseaseMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|October 2, 2010
Meta-analysis concludes angiotensin receptor blocker use increases the risk of developing cancer: concerns about the science and the messageMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|November 9, 2010
In navigator, the angiotensin receptor blocker valsartin modestly reduced the progression to type 2 diabetes but had no effect on cardiovascular events in higher-risk patients with impaired glucose toleranceMichael J Bloch, Jan N Basile
Journal of Clinical Hypertension (Greenwich, Conn.)|January 11, 2011
Treating the black hypertensive in 2010: achieve lower targets while awaiting more definitive evidenceMichael J Bloch, Jan N Basile
Pageof 68